We have therefore analyzed the effect of using the combination of novel, class selective cyclic amide-bearing hydroxamic acid based HDAC inhibitors SL142 or SL325 [17] combined with retinoic acids to test their efficacy for treating lung cancer. Here, HDAC9 is linked to lung carcinoma.